Best in Biotech 15 Aug 2024
10 neuroscience biotech companies you should know about
Learn more about nine of the top neuroscience biotech companies looking to develop treatments for difficult-to-treat neurological conditions.
Multiple sclerosis
- Latest Posts
In Depth 27 Mar 2024
Are new treatments for multiple sclerosis on the horizon?
As the wait for new multiple sclerosis treatments continue, here are some ongoing clinical trials that hold promise.
News and Trends 1 Jun 2023
Sanofi drug reduces disease activity in relapsing MS
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]
News and Trends 7 Dec 2022
Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years
Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]
News and Trends 28 Jul 2022
First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association
Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment for people with multiple sclerosis (MS). The application is for a biosimilar natalizumab developed by Polpharma Biologics and includes all indications covered by the reference […]
News and Trends 18 Jul 2022
First-ever Marketing Authorization Application for biosimilar targeting MS filed
An international biotech, with headquarters in Amsterdam, has announced that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for its biosimilar product. Polpharma Biologics, which is dedicated to the development of biosimilars, announced on Friday (July 15) that natalizumab, similar to Tysabri, which treats multiple sclerosis, has been accepted as […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 27 Apr 2021
EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]
News and Trends 11 Mar 2020
Phase III Fail for MedDay’s Multiple Sclerosis Treatment
A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial received either a placebo or a high dose of pharmaceutical-grade Biotin, also known as vitamin B₇. The patients had various forms of the autoimmune condition […]
News and Trends 17 Sep 2019
European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm
Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, […]
News and Trends 12 Mar 2019
Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis
An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research. GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, […]
News and Trends 19 Dec 2018
Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’
Altheia Science, based in Milan, has raised €17M to fund the development of gene therapies for autoimmune diseases with the remarkable potential to be curative. “The success of our fundraising campaign is unprecedented over a Series A in Italy,” said Paolo Rizzardi, co-founder and CEO of Altheia. The funds will go towards taking the company’s […]
More News! 18 May 2018
New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech
Spanish biotech Bionure has started an early stage trial of a new drug to treat rare neurologic eye diseases, which also shows promise for treatment of multiple sclerosis and other similar conditions. The therapy (BN201) is the first its class and if successful in clinical trials will be the only treatment that can help repair […]
ADVERTISEMENT